Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$7.02−0.08 (-1.13%)
Close on Nov 17, 2026Market cap $254.77MP/E –Yield –
Evommune r&d expenses
Research and development expenses are spending on new products and technology.
Evommune's R&D Expenses for the twelve months ending Sep 30, 2026 was $88.69M, up 24.1% year over year. For fiscal 2025 it was $74.04M, up 15.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.04M | +15.3% |
| FY2024 | Dec 31, 2024 | $64.24M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.55M | +25.0% |
| Q2 FY2026 | Jun 30, 2026 | $26.41M | +34.5% |
| Q1 FY2026 | Mar 31, 2026 | $17.32M | +20.6% |
| Q4 FY2025 | Dec 31, 2025 | $20.40M | +14.4% |
| Q3 FY2025 | Sep 30, 2025 | $19.64M | +47.8% |
| Q2 FY2025 | Jun 30, 2025 | $19.64M | – |
| Q1 FY2025 | Mar 31, 2025 | $14.36M | – |
| Q4 FY2024 | Dec 31, 2024 | $17.83M | – |
| Q3 FY2024 | Sep 30, 2024 | $13.29M | – |
See a number that looks wrong?